Last A$0.56 AUD
Change Today +0.035 / 6.60%
Volume 471.3K
BNO On Other Exchanges
Symbol
Exchange
OTC US
OTC US
Frankfurt
As of 1:50 AM 08/20/14 All times are local (Market data is delayed by at least 15 minutes).

bionomics ltd (BNO) Snapshot

Open
A$0.54
Previous Close
A$0.53
Day High
A$0.57
Day Low
A$0.54
52 Week High
12/2/13 - A$0.89
52 Week Low
06/4/14 - A$0.37
Market Cap
235.8M
Average Volume 10 Days
232.1K
EPS TTM
A$0.0080
Shares Outstanding
417.4M
EX-Date
--
P/E TM
70.6x
Dividend
--
Dividend Yield
--
Current Stock Chart for BIONOMICS LTD (BNO)

Related News

No related news articles were found.

bionomics ltd (BNO) Related Businessweek News

No Related Businessweek News Found

bionomics ltd (BNO) Details

Bionomics Limited, a biotechnology company, discovers and develops innovative therapeutics for the treatment of cancer and disorders of the central nervous system in Australia, France, and the United States. It develops small molecule and antibody programs in the areas of cancer, anxiety and memory loss. The company’s oncology approach includes cancer stem cell therapeutics, as well as vascular disruption in solid tumors. Its product pipeline includes BNC105, a novel compound that potently and selectively restricts blood flow within tumors that is in Phase II clinical trials for the treatment of solid tumors; BNC210, which is under development for the treatment of anxiety disorders; and Kv1.3 blockers for the treatment of multiple sclerosis, rheumatoid arthritis, psoriasis, and other autoimmune conditions. The company’s product pipeline also comprises alpha 7 nicotinic acetylcholine receptor modulators for the treatment of cognitive impairment in Alzheimer's disease and in Parkinson's disease. In addition, the company, through its subsidiary, Neurofit SAS, offers contract research services for various pharmaceutical and biotechnology companies. It has collaboration, research, and licensing agreement with Ironwood Pharmaceuticals, Inc. to develop and commercialize the company’s investigational anti-anxiety compound BNC210 and other related compounds; and a collaboration agreement with Cancer Therapeutics Cooperative Research Center. Bionomics Limited was founded in 1999 and is based in Thebarton, Australia.

Founded in 1999

bionomics ltd (BNO) Top Compensated Officers

Managing Director, Chief Executive Officer an...
Total Annual Compensation: A$419.8K
Chief Financial Officer and Company Secretary
Total Annual Compensation: A$156.0K
Chief Medical Officer
Total Annual Compensation: A$270.3K
Head of Neurofit Research
Total Annual Compensation: A$188.7K
Vice President of Research & Development
Total Annual Compensation: A$208.3K
Compensation as of Fiscal Year 2013.

bionomics ltd (BNO) Key Developments

Bionomics Ltd. Announces Audited Group Earnings Results for the Full Year Ended June 30, 2014

Bionomics Ltd. announced audited group earnings results for the full year ended June 30, 2014. For the year, the company reported revenue of $27,545,996, compared with $11,825,956 for the period to June 30, 2013. The operating profit after tax of the group for the period was $3,206,616 which was a result of the licensing of the BNC375 program to Merck & Co announced on June 24, 2014 and reflects the company's continued execution of its business plan.

Bionomics Enters USD 506 Million Drug Development Deal with Merck & Co

Bionomics has announced that it has entered into exclusive research collaboration and licensing agreement with Merck & Co (US) for its BNC375 research programme targeting cognitive dysfunction associated with Alzheimer's disease and other central nervous system (CNS) conditions. Under the agreement, Merck & Co will fund all research and development, including clinical development, and will be responsible for worldwide commercialization of any products from the collaboration. Bionomics will receive upfront payments totaling USD 20 million and is eligible to receive up to USD 506 million for meeting certain research and clinical development milestones as well as undisclosed royalties on any product sales.

Bionomics Announces Deal with Merck

Bionomics will receive more than $21 million from Merck as part of a deal to develop its treatment for Alzheimer's disease. Under the terms of the partnership arrangement Bionomics will receive an upfront sum of $20 million ($21.2 million), and could get up to $506 million ($537 million) if it hits certain research and development targets. Merck will manage the commercialization of products developed from the program and will have exclusive licensing rights. Bionomics will be paid royalties on global net product sales.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BNO:AU A$0.56 AUD +0.035

BNO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BNO.
View Industry Companies
 

Industry Analysis

BNO

Industry Average

Valuation BNO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 19.2x
Price/Book 6.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 19.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIONOMICS LTD, please visit www.bionomics.com.au. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.